BR9812433A - Kay- uma proteìna do sistema de imunização - Google Patents

Kay- uma proteìna do sistema de imunização

Info

Publication number
BR9812433A
BR9812433A BR9812433-1A BR9812433A BR9812433A BR 9812433 A BR9812433 A BR 9812433A BR 9812433 A BR9812433 A BR 9812433A BR 9812433 A BR9812433 A BR 9812433A
Authority
BR
Brazil
Prior art keywords
kay
protein
immunization system
immunization
tnf
Prior art date
Application number
BR9812433-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jurg Tschopp
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9812433A publication Critical patent/BR9812433A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9812433-1A 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização BR9812433A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
BR9812433A true BR9812433A (pt) 2000-09-26

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812433-1A BR9812433A (pt) 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização

Country Status (17)

Country Link
EP (1) EP1012270A2 (sk)
JP (1) JP2001515711A (sk)
KR (1) KR20010023892A (sk)
CN (1) CN1269832A (sk)
AU (1) AU9315298A (sk)
BR (1) BR9812433A (sk)
CA (1) CA2303424A1 (sk)
EA (1) EA200000311A1 (sk)
EE (1) EE200000148A (sk)
HU (1) HUP0004034A3 (sk)
IL (1) IL134480A0 (sk)
IS (1) IS5375A (sk)
NO (1) NO20001240L (sk)
PL (1) PL339740A1 (sk)
SK (1) SK3532000A3 (sk)
TR (1) TR200000654T2 (sk)
WO (1) WO1999012964A2 (sk)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999026463A2 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
JP2003526330A (ja) * 1999-02-23 2003-09-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ニュートロカイン−αおよびニュートロカイン−αスプライス改変体
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
KR100897082B1 (ko) * 1999-08-17 2009-05-14 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
PT1255558E (pt) 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294769B1 (en) 2000-06-16 2011-01-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2419661A1 (en) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
WO2005000351A2 (en) 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
EP1675609A1 (en) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Therapeutic regimens for baff antagonists
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
JP2008515890A (ja) 2004-10-05 2008-05-15 ジェネンテック・インコーポレーテッド 血管炎の治療方法
AU2005295713B2 (en) 2004-10-13 2011-06-16 The Washington University Use of BAFF to treat sepsis
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
AR059945A1 (es) 2005-08-09 2008-05-14 Zymogenetics Inc Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
AR059025A1 (es) 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
EP2230307A1 (en) * 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
IS5375A (is) 2000-02-11
KR20010023892A (ko) 2001-03-26
NO20001240D0 (no) 2000-03-09
HUP0004034A2 (en) 2001-03-28
AU9315298A (en) 1999-03-29
CA2303424A1 (en) 1999-03-18
WO1999012964A3 (en) 1999-05-27
NO20001240L (no) 2000-05-10
WO1999012964A2 (en) 1999-03-18
IL134480A0 (en) 2001-04-30
CN1269832A (zh) 2000-10-11
EP1012270A2 (en) 2000-06-28
TR200000654T2 (tr) 2000-07-21
EA200000311A1 (ru) 2000-10-30
PL339740A1 (en) 2001-01-02
EE200000148A (et) 2001-02-15
HUP0004034A3 (en) 2002-08-28
SK3532000A3 (en) 2001-12-03
JP2001515711A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
BR9812433A (pt) Kay- uma proteìna do sistema de imunização
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BR9814276A (pt) Antìgenos de superfìcie
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
ATE83663T1 (de) Imipramin enthaltende arzneizubereitungen.
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
WO2004019872A3 (en) Oral delivery of modified transferrin fusion proteins
BR9606674B1 (pt) novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo.
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
BR9808625A (pt) O uso de proteìnas extraìveis de órgãos de animal para a preparação de medicamentos para o tratamento de condições patológicas caracterizadas por hiperprodução de fator de necrose de tumor (tnf)
PT952982E (pt) Novos inibidores da hepatite b
BG104452A (en) New derivatives of the methylenebisphosphonic acid
ES2089091T3 (es) Complejos que contienen acidos s(+)-fenilalcanoicos y acidos alfa-hidroalcanoicos.
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
DK1019500T3 (da) IFN receptor 1-bindende proteiner, DNA, som koder for dem, og fremgangsmåder til modulering af cellulært respons på interferoner
BR1101039A (pt) Composição farmacêutica para doenças renais ou cardiovasculares
NL1008181A1 (nl) Medische inrichting ter applicatie van vloeistoffen.
IT1295562B1 (it) Sistema di montaggio, smontaggio e componibilita' di sedie

Legal Events

Date Code Title Description
PC Transfer

Free format text: APOTECH R&D S.A. (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.